Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
GRFS 
Grifols SA ADR (GRFS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: GRFS (1-star) is a SELL. SELL since 4 days. Profits (-11.71%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -43.92% | Avg. Invested days 38 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.13B USD | Price to earnings Ratio 35 | 1Y Target Price 10.67 |
Price to earnings Ratio 35 | 1Y Target Price 10.67 | ||
Volume (30-day avg) 1261351 | Beta 0.69 | 52 Weeks Range 5.79 - 9.96 | Updated Date 03/31/2025 |
52 Weeks Range 5.79 - 9.96 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 2.31% | Operating Margin (TTM) 20.06% |
Management Effectiveness
Return on Assets (TTM) 2.87% | Return on Equity (TTM) 2.71% |
Valuation
Trailing PE 35 | Forward PE 11.48 | Enterprise Value 15373859996 | Price to Sales(TTM) 0.76 |
Enterprise Value 15373859996 | Price to Sales(TTM) 0.76 | ||
Enterprise Value to Revenue 1.97 | Enterprise Value to EBITDA 9.57 | Shares Outstanding 257444000 | Shares Floating 547937449 |
Shares Outstanding 257444000 | Shares Floating 547937449 | ||
Percent Insiders - | Percent Institutions 58.25 |
Analyst Ratings
Rating 3.67 | Target Price 10.67 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Grifols SA ADR
Company Overview
History and Background
Grifols was founded in Barcelona, Spain, in 1909. It is a global healthcare company specializing in plasma-derived medicines and related services. Initially a small laboratory, Grifols expanded through innovation and strategic acquisitions, becoming a leading player in the plasma industry.
Core Business Areas
- Bioscience: This is Grifols' core business, focusing on the production of plasma-derived therapies for various medical conditions like immunodeficiencies, bleeding disorders, and neurological diseases.
- Diagnostic: This segment develops and manufactures in-vitro diagnostic products for transfusion medicine, blood typing, and clinical diagnostics.
- Hospital: This segment focuses on providing hospital pharmacy products and services including IV solutions, nutritional products, and medical devices.
- Biomaterials: This division researches, develops, manufactures and markets products for therapeutic applications in the field of tissue regeneration, wound healing and surgery.
Leadership and Structure
Grifols is led by a Board of Directors. The management team is responsible for day-to-day operations. Key figures include the CEO and executives heading each business division.
Top Products and Market Share
Key Offerings
- Albumin: Used for treating hypovolemia and hypoalbuminemia. Grifols is a major global producer. Competitors include CSL Behring and Takeda. Market Share is confidential.
- Intravenous Immunoglobulin (IVIG): Used to treat immune deficiencies and autoimmune disorders. Grifols is a significant player in this market. Competitors include CSL Behring, Takeda, and Octapharma. Market Share is confidential.
- Alpha-1 Antitrypsin (AAT): Used to treat Alpha-1 antitrypsin deficiency. Grifols is a leader with Prolastin-C. Competitors include CSL Behring. Market Share is confidential.
- Factor VIII: Used to treat Hemophilia A. Grifols is a competitor with Alphanate. Competitors include Novo Nordisk, Roche, and Bayer. Market Share is confidential.
Market Dynamics
Industry Overview
The plasma-derived therapies market is growing due to increasing prevalence of chronic diseases, aging populations, and advancements in diagnostic technologies. It's highly regulated and capital-intensive.
Positioning
Grifols is a leading player in the plasma-derived therapies market, with a strong global presence and a diversified product portfolio. Their vertically integrated model provides a competitive advantage.
Total Addressable Market (TAM)
The global plasma fractionation market is projected to reach hundreds of billions. Grifols, being a major player, captures a significant portion. Market analysis shows a multi-billion dollar market, with a significant portion accessible to Grifols.
Upturn SWOT Analysis
Strengths
- Global Leader in Plasma-Derived Therapies
- Vertically Integrated Business Model
- Strong R&D Capabilities
- Diversified Product Portfolio
- Established Global Presence
Weaknesses
- High Debt Levels
- Dependence on Plasma Supply
- Regulatory Scrutiny
- Competition from Larger Players
Opportunities
- Expanding into Emerging Markets
- Developing New Plasma-Derived Therapies
- Acquiring Smaller Competitors
- Increasing Demand for Immunoglobulin
Threats
- Fluctuations in Plasma Supply
- Pricing Pressures
- Generic Competition
- Changes in Healthcare Regulations
Competitors and Market Share
Key Competitors
- CSL (CSLLY)
- Takeda Pharmaceutical Company Limited (TAK)
- Octapharma
Competitive Landscape
Grifols benefits from vertical integration in plasma collection. However, it faces competitive pressures from larger pharmaceutical companies and evolving regulatory landscape.
Major Acquisitions
Tiancheng (Germany)
- Year: 2018
- Acquisition Price (USD millions): 220
- Strategic Rationale: Expanded Grifols' fractionation capacity and market access.
Haemacure Corporation
- Year: 2011
- Acquisition Price (USD millions): 94
- Strategic Rationale: Acquisition of surgical and wound-closure products
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by increasing demand for plasma-derived therapies and strategic acquisitions.
Future Projections: Future growth is projected to be driven by expansion into emerging markets and the development of new therapies. Analyst estimates vary.
Recent Initiatives: Recent initiatives include expanding plasma collection centers, investing in R&D, and pursuing strategic partnerships.
Summary
Grifols is a significant player in the plasma-derived therapies market, with a vertically integrated business model and strong R&D. Its high debt levels pose a challenge, but the company is poised for continued growth through expansion and new product development. It needs to carefully monitor fluctuations in plasma supply, and increased competition from larger competitors.
Similar Companies
TAK
Takeda Pharmaceutical Co Ltd ADR
TAK
Takeda Pharmaceutical Co Ltd ADR
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
- Financial News Sources
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Grifols SA ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2006-05-17 | CEO & Director Mr. Jose Ignacio Abia Buenache | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 23833 | Website https://www.grifols.com |
Full time employees 23833 | Website https://www.grifols.com | ||
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties. In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug. Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL; Prolastin-C AADT and Fostamatinib; Xembify " CLL, Albumina 20% and 5%, and Trimodulin; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290; GIGA 2339 and GIGA564; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage. It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.